Personalised Prostate Cancer Screening is a new healthcare service that innovatively uses prostate cancer polygenic risk score (PRS) testing with family cancer history and, where indicated, monogenic pathogenic variant testing.
It identifies men at high genetic risk who, alongside PSA testing, should undergo more detailed investigations such as MRI for earlier detection.
The service is intended for men aged 40 to 70.
The service integrates the assessment of genetic risk for prostate cancer – comprising both polygenic risk and, where indicated, the evaluation of monogenic pathogenic variants – into the existing EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. This represents a more precise advancement of the current approach. The subsequent diagnostic pathway would take genetic risk into account, while the rest of the guideline’s recommendations and overall concept would remain unchanged.
As a result of the service, with the support of digital decision support, the man and his doctor will receive a personalised screening plan based on a personal risk level as a health service.
This approach is not based on binary decisions. Prostate cancer risk exists on a continuum, and personalised prevention requires a risk-stratified framework that takes genetic risk, age, family background, and clinical context into account. Clear decision support is therefore essential for both patients and healthcare professionals.
The service is implemented in several European healthcare systems.
If you have any questions or would like further information on clinical use, please contact our team.
"*" indicates required fields
